Pfizer Finance Chief Dave Denton Resigns for Consumer Goods

Pharmaceutical heavyweight Pfizer has announced the departure of its Executive Vice President and Chief Financial Officer, Dave Denton. 

He will step down from his role on 15 August to pursue a new corporate opportunity within the consumer goods sector.

The New York-listed company has appointed Cecile Guegan, currently Senior Vice President of Finance for the global biopharmaceutical business, to step into the Chief Financial Officer role on an interim basis from 16 August. 

Pfizer is launching a comprehensive internal and external executive search to identify a permanent successor. To maintain stability, Dave and Cecile will collaborate closely during the transition window to ensure an orderly handover of responsibilities.

The executive transition

Dave’s departure marks the end of a pivotal chapter for Pfizer's capital allocation and balance sheet strategy. During his tenure, the finance chief oversaw substantial deal-making activities that reshaped the firm's portfolio.

Albert Bourla, Chairman and CEO of Pfizer, acknowledges Denton's contributions to the company's financial structure. 

He comments:  “Dave has been a steady and trusted steward of Pfizer’s financial health, and we are grateful for his leadership, especially during some of the most important business transactions in our recent history, including Seagen, Biohaven and Metsera, that will serve Pfizer well for years to come. 

“We wish him the very best as he returns to the consumer goods industry.”

The chief executive expressed complete assurance regarding the interim leadership. 

Albert continues: “Given Cecile’s deep institutional knowledge and financial acumen, I have every confidence in her ability to lead Pfizer's finance organisation and keep us focused on what matters most – executing our strategy and delivering for patients and shareholders.” 

A case of corporate continuity

Cecile Guegan takes the financial helm with more than two decades of operational experience inside Pfizer.

She has spent her career navigating complex global portfolios, research and development budgets and varied regional divisions. 

In her current capacity, she commands direct oversight of the financial operations and reporting structures for the group's biopharmaceutical business, which spans all therapeutic segments and global markets.

Her track record includes driving major corporate integration projects, notably leading the financial unification of oncology specialist Seagen after its acquisition in 2024. Cecile holds a Master in Business degree from Brest Business School.

Reflecting on his departure, Dave Denton, Executive Vice President and outgoing Chief Financial Officer, expresses confidence in the company's financial leadership moving forward:  “It has been an honour and privilege to work alongside Albert for Pfizer, an iconic and purpose-driven company, during such a meaningful time in its history.

 “Pfizer is in excellent hands, and I leave knowing the executive leadership team, now including Cecile as interim CFO, will continue to succeed and carry its important work forward.”

The leadership shift arrives as Pfizer continues to embed its recent multi-billion dollar acquisitions into its broader biopharmaceutical operations. 

The incoming finance chief will remain focused on operational execution, cost management and capital deployment strategies across Pfizer's massive global commercial pipeline while the board evaluates long-term candidates both internally and externally.